Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Development of a new vaccine for the prevention of Lassa fever
Thomas W. Geisbert
, Steven Jones
, Elizabeth A. Fritz
, Amy C. Shurtleff
, Joan B. Geisbert
, Ryan Liebscher
, Allen Grolla
, Ute Ströher
, Lisa Fernando
, Kathleen M. Daddario
, Mary C. Guttieri
, Bianca R. Mothé
, Tom Larsen
, Lisa E. Hensley
, Peter B. Jahrling
, Heinz Feldmann
Research output
:
Contribution to journal
›
Article
›
peer-review
233
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Development of a new vaccine for the prevention of Lassa fever'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Next-generation Vaccines
100%
Lassa Fever
100%
Lassa
100%
Monkey
33%
Nonhuman Primate
33%
Recombinant Vesicular Stomatitis Virus
33%
Lassa Virus
33%
Humoral Immune Response
16%
Cellular Immune Response
16%
United States
16%
Illness
16%
Public Health Risk
16%
Vaccination
16%
Protective Immune Response
16%
Human Disease
16%
Vaccine Candidate
16%
Fever
16%
Virus Challenge
16%
Clinical Disease
16%
Viral Glycoprotein
16%
Lethal Challenge
16%
Mandatory Vaccines
16%
Vaccine Response
16%
Viremia
16%
Africa
16%
Travellers
16%
Replication-competent
16%
Emerging Viruses
16%
Rash
16%
Germany
16%
Netherlands
16%
Intramuscular Vaccination
16%
Vesicular Stomatitis Virus Vector
16%
Elevated Liver Enzymes
16%
Experimental Vaccines
16%
Commercial Airlines
16%
Vaccine Virus Shedding
16%
Severe Symptoms
16%
United Kingdom
16%
Facial Edema
16%
Immunology and Microbiology
Vesiculovirus
100%
Lassa Virus
100%
Humoral Immunity
50%
Adoptive Immunity
50%
Immune Response
50%
Glycoprotein
50%
Viremia
50%
Viral Vector
50%
Emerging Viruses
50%
Replication
50%
Infection
50%
Pharmacology, Toxicology and Pharmaceutical Science
Lassa Fever
100%
Diseases
100%
Vesiculovirus
66%
Lassa Virus
66%
Infection
33%
Glycoprotein
33%
Viral Vector
33%
Viremia
33%
Rash
33%
Face Edema
33%
Hypertransaminasemia
33%